More private capital is flowing into the life sciences sector, valuations are up, financing terms have become more startup friendly and the use of tranching is down, according to a report by law firm Cooley LLP. "The supply and demand balance has shifted towards suppliers of innovation (and thus issuers of equity) in the face of robust capital flows," venture capitalist Bruce Booth writes.
Sign up for FasterCures SmartBrief
Medical research news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.